Kukje Pharma said on the 23rd that it appointed Chief Executive Officer Nam Tae-hoon, the third-generation Oner, as vice chairman. Nam, the vice chairman, joined Kukje Pharma in 2009 and worked in marketing, sales, and administration. He became CEO in 2017.
Nam, the vice chairman, will oversee mid- to long-term growth strategy, including serving as chief operating officer (COO). The company said it carried out regular executive appointments to strengthen future competitiveness. The industry assessed that with this reshuffle, Kukje Pharma is accelerating its management succession.
Executives in the technology and research and development institutional sector were also promoted this time. Chief Technology Officer (CTO) Kim Young-gwan was promoted from senior managing director to executive vice president. Kim, the executive vice president who joined in 1992, is in charge of new drug development. Managing Director Kim Young-hoon oversees the research and development organization, focusing on operating the central research institute.
A Kukje Pharma official said, "These personnel moves aim to strengthen the execution of core businesses," adding, "We will establish a foundation for sustainable growth based on research and development."